GlassScriptPhysician profile
Natassa L Quinn
NPI 1881630796
$11,679.42
in general payments reported to CMS, 2019-2025
52 companies · $1,771 in 2025
The $1,771 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,711 · 2020: $1,469 · 2021: $2,114 · 2022: $1,548 · 2023: $1,322 · 2024: $1,745 · 2025: $1,771.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,839.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,838.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,791.63 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,246.35 | 2019-2025 | |
| Pfizer INC. | $1,199.13 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,056.50 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Lilly USA, LLC | $1,046.97 | 2019-2025 | Zepbound, Jardiance, Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $554.18 | 2021-2025 | |
| Exact Sciences Corporation | $430.29 | 2023-2025 | Cologuard Collection Kit |
| Biohaven Pharmaceuticals, INC. | $388.12 | 2020-2021 | |
| Astellas Pharma US INC | $347.57 | 2019-2024 | Veozah, Myrbetriq |
| Glaxosmithkline, LLC. | $345.75 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $245.62 | 2019-2025 | Gardasil 9, Gardasil, Capvaxive |
| Boehringer Ingelheim Pharmaceuticals, INC. | $210.42 | 2019-2024 | Jardiance, Tradjenta, Synjardy |
| Takeda Pharmaceuticals U.S.A., INC. | $198.53 | 2019-2022 | |
| Inspire Medical Systems, INC. | $196.99 | 2024-2025 | Inspire |
| Allergan, INC. | $195.45 | 2019-2020 |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Natassa Quinn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.